EyePoint Pharmaceuticals, Inc. (EYPT) is a specialty biopharmaceutical company that has made a name for itself in the development and commercialization of ophthalmic products for treating a diverse array of eye diseases. Formerly known as P.S.I.Vida Inc., the company was founded in 1987 and rebranded to EyePoint Pharmaceuticals in 2018. Its headquarters are located in Watertown, Massachusetts.
EYPT has made significant strides in the research, development, and commercialization of innovative and effective treatments for severe eye diseases. Their primary focus is on creating drugs that will have a long-lasting impact, aiming to reduce the burden of frequent administration and improve the quality of life for patients.
The firm's portfolio includes two main products: DEXYCU and YUTIQ. DEXYCU is an intraocular suspension used post cataract surgery to curb inflammation. It is the first long-acting intraocular product approved by the Food and Drug Administration (FDA) for postoperative inflammation. YUTIQ, on the other hand, is a micro-insert designed to deliver fluocinolone acetonide, a corticosteroid, to the back of the eye, for treating patients suffering from chronic non-infectious uveitis affecting the posterior segment of the eye. It is a three-year treatment, also approved by the FDA.
Moreover, EyePoint Pharmaceuticals is involved in developing EYP-1901. This is another bioerodible formulation under phase 1 clinical trial designed for potential six-month sustained delivery of vorolanib, targeted at disrupting the development of neovascular age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion.
The company has strong tie-ups with partners, including tier-1 companies within the industry, aimed at utilizing its proprietary bioerodible Durasert™ technology to bring new products to the market. These collaborations expand worldwide and are integral to the company's growth and expansion strategy.
EYPT is publicly traded on the NASDAQ Global Market under the ticker symbol 'EYPT'. The firm is committed to addressing the unmet needs within the ophthalmology market and enriching the patient experience with their innovative products. The commitment of EyePoint Pharmaceuticals to their mission of enabling better vision and quality of life sets them apart in the competitive biopharmaceutical industry.